NanoViricides, Inc. (NYSE American: NNVC) announced that its clinical lead drug candidate NV-387 demonstrated potent antiviral effects against the measles virus in both cell culture studies and a humanized animal model. The drug treatment extended survival in infected mice by 130%, from 7.4 to 17 days, while significantly protecting lung tissue from viral and immune-related damage.
The drug's dual action—direct viral suppression and mitigation of systemic and lung inflammation—showed reduced lung plaques, slower disease progression and improved overall health outcomes in treated animals. Currently, no approved drug exists for measles treatment, underscoring NV-387's potential as a first-in-class therapeutic candidate. This development is particularly significant given the global resurgence of measles outbreaks in recent years and the limitations of current prevention-focused approaches.
NanoViricides is a clinical stage company creating special purpose nanomaterials for antiviral therapy. The company's novel nanoviricide class of drug candidates and technology are based on intellectual property from TheraCour Pharma, Inc. The company has obtained broad, exclusive, sub-licensable field licenses to drugs developed in several licensed fields from TheraCour Pharma, Inc. according to their corporate information available at https://www.nanoviricides.com.
NV-387 represents a broad-spectrum antiviral drug that the company plans to develop as a treatment for RSV, COVID, Long COVID, Influenza, and other respiratory viral infections, as well as MPOX/Smallpox infections. The company is currently focused on advancing NV-387 into Phase II human clinical trials. The successful preclinical results against measles add another potential application for this versatile drug candidate.
The implications of these findings extend beyond measles treatment alone. The demonstrated lung-protective properties of NV-387 could have broader applications for respiratory viral diseases where lung inflammation and damage represent significant clinical challenges. The dual mechanism of action—combining direct antiviral effects with anti-inflammatory properties—represents a novel approach that could potentially address both the viral infection and the damaging immune response that often accompanies severe viral illnesses.
For investors and stakeholders following the company's progress, additional information and updates relating to NNVC are available through the company's newsroom at https://ibn.fm/NNVC. The path to drug development remains lengthy and requires substantial capital, with no assurance that preclinical success will translate to effective human treatments. However, the current results position NV-387 as a promising candidate in the antiviral therapeutic landscape.
